Myomo (NYSEAMERICAN:MYO) reported second-quarter 2026 revenue growth of 21% as the wearable robotics company continued shifting its patient acquisition strategy toward recurring referral sources and expanded reimbursement relationships. Management raised full-year 2026 revenue guidance to $45 million–$47 million , up from $43 million–$46 million, and expects third-quarter revenue of $11.5 million–$12 million. Gudonis said the company expects full publication of the trial results in 2027. Outlook RaisedFor the third quarter, Myomo expects revenue of $11.5 million to $12 million, representing year-over-year growth of 14% to 19%. The article "Myomo Q2 Earnings Call Highlights" was originally published by MarketBeat.